PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2020

Intravenous Immunomodulatory Nanoparticle Treatment for Traumatic Brain Injury

Mouse / TBI

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 31925846 ↗2020Reported benefit

Intravenous Immunomodulatory Nanoparticle Treatment for Traumatic Brain Injury

MouseTBIControlled cortical impactC57BL/6 (wild-type, Charles River)Malen = 5 mice pooled per experiment for each flow cytometry analys…Intravenous (lateral tail vein)200 microlitres of a 4.7 mg/ml suspension in sterile isoton…First infusion 2 to 3 hours after injury

Model: Two experimental traumatic brain injury models: controlled cortical impact (3 mm craniotomy, 2 mm impactor tip, 2 mm cortical deformation at 3.00 m/s with 30 second dwell, targeting visual or sensorimotor cortex) and moderate weight-drop closed head injury (240 g weight dropped 1.4 m onto the anaesthetised mouse resting on prescored foil)

In controlled cortical impact, nanoparticle treatment cut total cells in the lesion area by 44.0%, infiltrating macrophages/monocytes by 84.5%, overall myeloid cells by 65.8% and Ly6C inflammatory monocytes by 72.4% at 72 hours, and reduced lesion volume by 44.7% at 10 weeks with a less intense per…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.